medical news

Baudax Bio Prepares for Pioneering Clinical Development of TI-168, Aiming to Improve Hemophilia A Treatment

MALVERN, PA — In a significant corporate update, Chester County-based biotechnology firm Baudax Bio, Inc. (NASDAQ: BXRX) this week announced plans to initiate the clinical development of its groundbreaking therapy, …

Baudax Bio Prepares for Pioneering Clinical Development of TI-168, Aiming to Improve Hemophilia A Treatment Read More

Baudax Bio, Inc.



Baudax Bio, Inc.

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000

MALVERN, PA — Baudax Bio, Inc. (Nasdaq: BXRX), a pharmaceutical company, announced additional results from its Phase 2 clinical trial of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective …

Baudax Bio Announces Additional, Positive Top-Line Results From Phase 2 Randomized Clinical Trial of BX1000 Read More